|
1
|
Cho JY: Molecular diagnosis for
personalized target therapy in gastric cancer. J Gastric Cancer.
13:129–135. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Nagini S: Carcinoma of the stomach: A
review of epidemiology, pathogenesis, molecular genetics and
chemoprevention. World J Gastrointest Oncol. 4:156–169. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Yatsuya H, Toyoshima H, Mizoue T, Kondo T,
Tamakoshi K, Hori Y, Tokui N, Hoshiyama Y, Kikuchi S, Sakata K, et
al: Family history and the risk of stomach cancer death in Japan:
Differences by age and gender. Int J Cancer. 97:688–694. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Halasi M and Gartel AL: Targeting FOXM1 in
cancer. Biochem Pharmacol. 85:644–652. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Alvarez-Fernández M and Medema RH: Novel
functions of FoxM1: From molecular mechanisms to cancer therapy.
Front Oncol. 3:302013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Huang C, Xie D, Cui J, Li Q, Gao Y and Xie
K: FOXM1c promotes pancreatic cancer epithelial-to-mesenchymal
transition and metastasis via upregulation of expression of the
urokinase plasminogen activator system. Clin Cancer Res.
20:1477–1488. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Yang C, Chen H, Tan G, Gao W, Cheng L,
Jiang X, Yu L and Tan Y: FOXM1 promotes the epithelial to
mesenchymal transition by stimulating the transcription of Slug in
human breast cancer. Cancer Lett. 340:104–112. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Li D, Wei P, Peng Z, Huang C, Tang H, Jia
Z, Cui J, Le X, Huang S and Xie K: The critical role of
dysregulated FOXM1-PLAUR signaling in human colon cancer
progression and metastasis. Clin Cancer Res. 19:62–72. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Li X, Tang D, Yao Y, Qi W and Liang J:
Clinical significance and positive correlation of FoxM1 and Her-2
expression in gastric cancer. Clin Exp Med. 14:447–455. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Li Q, Zhang N, Jia Z, Le X, Dai B, Wei D,
Huang S, Tan D and Xie K: Critical role and regulation of
transcription factor FoxM1 in human gastric cancer angiogenesis and
progression. Cancer Res. 69:3501–3509. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Yu C, Chen L, Yie L, Wei L, Wen T, Liu Y
and Chen H: Targeting FoxM1 inhibits proliferation, invasion and
migration of nasopharyngeal carcinoma through the
epithelialto-mesenchymal transition pathway. Oncol Rep.
33:2402–2410. 2015.PubMed/NCBI
|
|
12
|
Meng FD, Wei JC, Qu K, Wang ZX, Wu QF, Tai
MH, Liu HC, Zhang RY and Liu C: FoxM1 overexpression promotes
epithelial-mesenchymal transition and metastasis of hepatocellular
carcinoma. World J Gastroenterol. 21:196–213. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Bhatt T, Rizvi A, Batta SP, Kataria S and
Jamora C: Signaling and mechanical roles of E-cadherin. Cell Commun
Adhes. 20:189–199. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Yang SW, Ping YF, Jiang YX, Luo X, Zhang
X, Bian XW and Yu PW: ATG4A promotes tumor metastasis by inducing
the epithelial-mesenchymal transition and stem-like properties in
gastric cells. Oncotarget. Jun 4–2016.(Epub ahead of print).
|
|
15
|
Yu H, Shen Y, Hong J, Xia Q, Zhou F and
Liu X: The contribution of TGF-β in Epithelial-Mesenchymal
Transition (EMT): Down-regulation of E-cadherin via snail.
Neoplasma. 62:1–15. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Markiewicz A, Wełnicka-Jaśkiewicz M,
Seroczyńska B, Skokowski J, Majewska H, Szade J and Żaczek AJ:
Epithelial-mesenchymal transition markers in lymph node metastases
and primary breast tumors-relation to dissemination and
proliferation. Am J Transl Res. 6:793–808. 2014.PubMed/NCBI
|
|
17
|
Bella L, Zona S, de Moraes G Nestal and
Lam EW: FOXM1: A key oncofoetal transcription factor in health and
disease. Semin Cancer Biol. 29:32–39. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Huang C, Du J and Xie K: FOXM1 and its
oncogenic signaling in pancreatic cancer pathogenesis. Biochim
Biophys Acta. 1845:104–116. 2014.PubMed/NCBI
|
|
19
|
Koo CY, Muir KW and Lam EW: FOXM1: From
cancer initiation to progression and treatment. Biochim Biophys
Acta. 1819:28–37. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Chu XY, Zhu ZM, Chen LB, Wang JH, Su QS,
Yang JR, Lin Y, Xue LJ, Liu XB and Mo XB: FOXM1 expression
correlates with tumor invasion and a poor prognosis of colorectal
cancer. Acta Histochem. 114:755–762. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Huang C, Qiu Z, Wang L, Peng Z, Jia Z,
Logsdon CD, Le X, Wei D, Huang S and Xie K: A novel FoxM1-caveolin
signaling pathway promotes pancreatic cancer invasion and
metastasis. Cancer Res. 72:655–665. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wei P, Zhang N, Wang Y, Li D, Wang L, Sun
X, Shen C, Yang Y, Zhou X and Du X: FOXM1 promotes lung
adenocarcinoma invasion and metastasis by upregulating SNAIL. Int J
Biol Sci. 11:186–198. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wang Y, Yao B, Wang Y, Zhang M, Fu S, Gao
H, Peng R, Zhang L and Tang J: Increased FoxM1 expression is a
target for metformin in the suppression of EMT in prostate cancer.
Int J Mol Med. 33:1514–1522. 2014.PubMed/NCBI
|
|
24
|
Kong FF, Zhu YL, Yuan HH, Wang JY, Zhao M,
Gong XD, Liu F, Zhang WY, Wang CR and Jiang B: FOXM1 regulated by
ERK pathway mediates TGF-β1-induced EMT in NSCLC. Oncol Res.
22:29–37. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
van Roy F: Beyond E-cadherin: Roles of
other cadherin superfamily members in cancer. Nat Rev Cancer.
14:121–134. 2014. View
Article : Google Scholar : PubMed/NCBI
|
|
26
|
Nakagawa H, Hikiba Y, Hirata Y,
Font-Burgada J, Sakamoto K, Hayakawa Y, Taniguchi K, Umemura A,
Kinoshita H, Sakitani K, et al: Loss of liver E-cadherin induces
sclerosing cholangitis and promotes carcinogenesis. Proc Natl Acad
Sci USA. 111:1090–1095. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zhou Y, Ming J, Xu Y, Zhang Y and Jiang J:
ERβ1 inhibits the migration and invasion of breast cancer cells
through upregulation of E-cadherin in a Id1-dependent manner.
Biochem Biophys Res Commun. 457:141–147. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Tang W, Zhu Y, Gao J, Fu J, Liu C, Liu Y,
Song C, Zhu S, Leng Y, Wang G, et al: MicroRNA-29a promotes
colorectal cancer metastasis by regulating matrix metalloproteinase
2 and E-cadherin via KLF4. Br J Cancer. 110:450–458. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Zhai X, Zhu H, Wang W, Zhang S, Zhang Y
and Mao G: Abnormal expression of EMT-related proteins, S100A4,
vimentin and E-cadherin, is correlated with clinicopathological
features and prognosis in HCC. Med Oncol. 31:9702014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Wierstra I: The transcription factor
FOXM1c binds to and transactivates the promoter of the tumor
suppressor gene E-cadherin. Cell Cycle. 10:760–766. 2011.
View Article : Google Scholar : PubMed/NCBI
|
